AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34736789
Drug: Receiver operating
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receiver operating characteristic analysis of soluble urokinase plasminogen activator receptor
Trial: 34736789
Drug: Adding soluble
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adding soluble urokinase plasminogen activator receptor to the model
Trial: 34737035
Drug: Persistently low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Persistently low hsCRP (hsCRP ≤ 2 mg/L)
Trial: 34737035
Drug: Persistently high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Persistently high hsCRP (hsCRP > 2 mg/L)
Trial: 34738141
Drug: Bevacizumab-800CW (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab-800CW (10 mg intravenously administered 3 days prior to surgery)
Trial: 34739527
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g Vitamin C 4 times a day during 4 days, started within 6 hours after admission
Trial: 36037567
Drug: Lurbinectedin 3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurbinectedin 3.2 mg/m
Trial: 34739844
Drug: Ibrutinib plus
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib plus R-CHOP chemotherapy
Trial: 34739844
Drug: R-CHOP chemotherapy
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP chemotherapy alone
Trial: 34740768
Drug: Salvage low-dose-rate
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage low-dose-rate (LDR) prostate brachytherapy (BT)
Trial: 34741102
Drug: IV sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV sildenafil 0.25 mg/kg (cohort 2)
Trial: 34741102
Drug: IV sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV sildenafil 0.125 mg/kg (cohort 2)
Trial: 34741172
Drug: CAPA-AREG (medium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAPA-AREG (medium with amphiregulin 100 ng/ml)
Trial: 34741321
Drug: Transcortical miniscrew
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcortical miniscrew placed over the buccal plate of the extraction socket
Trial: 34741822
Drug: Permanent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permanent treatment discontinuation
Trial: 34741822
Drug: Dose or
RxNorm normalized name: Oxydose Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose or regimen adjustment
Trial: 34742157
Drug: BNT162b2 SARS-CoV-2
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 SARS-CoV-2 vaccination (two doses)
Trial: 34745093
Drug: Dornase alfa
RxNorm normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dornase alfa (inhaled)
Trial: 34746207
Drug: Infliximab treatment
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab treatment without Vitamin D3 supplementation
Trial: 34746903
Drug: Bempedoic acid
RxNorm normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bempedoic acid 180 mg plus ezetimibe 10 mg fixed-dose combination (BA + EZE FDC)
Trial: 34747267
Drug: Topical Oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Oxygen Therapy (Natrox)
Trial: 34748385
Drug: Clofazimine, dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofazimine, dosage and duration not specified
Trial: 34748634
Drug: Severe insulin-resistant
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Severe insulin-resistant diabetes (SIRD)
Trial: 34748672
Drug: Ocrelizumab 600
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ocrelizumab 600 mg intravenous every 24 weeks for 96 weeks
Trial: 34748951
Drug: 50 ml
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml Extra Virgin Olive Oil (EVOO) daily for one year
Trial: 34748951
Drug: Not administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not administered EVOO (Control group)
Trial: 34749777
Drug: Personalized pharmaceutical
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Personalized pharmaceutical plan (PPP) implemented in the intervention phase, including drug reconciliation, daily follow-up, and post-transplantation meetings.
Trial: 34749777
Drug: Control phase
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control phase with no personalized pharmaceutical plan.
Trial: 34749788
Drug: Home-based diabetes-modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based diabetes-modified behavioral activation treatment (HOME DM-BAT) using in-home, nurse telephone-delivered diabetes education and behavioral activation.
Trial: 34749788
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care group using in-home, nurse telephone-delivered health education/supportive therapy.
Trial: 34749885
Drug: Checkpoint inhibitor
RxNorm normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Checkpoint inhibitor therapy
Trial: 34750057
Drug: Esketamine nasal
RxNorm normalized name: esketamine Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine nasal spray (ESK) plus oral antidepressant during induction phase (4 weeks)
Trial: 34750057
Drug: Esketamine nasal
RxNorm normalized name: esketamine Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine nasal spray (ESK) plus oral antidepressant during optimization/maintenance phase (week 12)
Trial: 34750057
Drug: Treatment-emergent adverse
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-emergent adverse events (TEAEs) during induction phase
Trial: 34750057
Drug: Treatment-emergent adverse
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-emergent adverse events (TEAEs) during optimization/maintenance phase
Trial: 34750081
Drug: Evolocumab 420
RxNorm normalized name: evolocumab 420 in 3.5 ML Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab 420 mg subcutaneously monthly (every 2 weeks if on apheresis)
Trial: 34750296
Drug: Romidepsin (RMD)
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romidepsin (RMD) as latency-reversing agent
Trial: 34750494
Drug: Multi-Arm Sequential
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-Arm Sequential Trial with Efficient Recruitment (MASTER) design
Trial: 34750557
Drug: Durvalumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab plus platinum-pemetrexed chemotherapy
Trial: 34750557
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and pemetrexed chemotherapy (historical control)
Trial: 34750637
Drug: Dostarlimab 1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dostarlimab 1, 3, or 10 mg/kg intravenously every 2 weeks (part 1)
Trial: 34750637
Drug: Dostarlimab 500
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dostarlimab 500 mg every 3 weeks (Q3W)
Trial: 34750637
Drug: Dostarlimab 1000
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dostarlimab 1000 mg every 6 weeks (Q6W)
Trial: 34750637
Drug: Dostarlimab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dostarlimab (all doses)
Trial: 34751002
Drug: Adjuvant systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant systemic therapy (AST) discussion referrals
Trial: 34751002
Drug: Adjuvant immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant immunotherapy trials
Trial: 34751259
Drug: ChAdOx1 MERS
RxNorm normalized name: mersalyl
DrugBank: Mersalyl (DB09338)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1 MERS vaccine (single intramuscular injection)
Trial: 34752491
Drug: Machine Learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine Learning (ML) and Deep Learning (DL) approaches applied to fetuses and newborns with CDH for predicting neonatal pulmonary hypertension (PH)
Trial: 34752491
Drug: Machine Learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine Learning (ML) and Deep Learning (DL) approaches
Trial: 34753703
Drug: Cetuximab added
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab added to first-line chemotherapy (CT) in SCC patients with positive EGFR FISH and IHC (N=58)
Trial: 34753762
Drug: Daily administration
RxNorm normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration of an unspecified intervention (not detailed in the abstract)
Trial: 34753777
Drug: Mogamulizumab 1
RxNorm normalized name: mogamulizumab
DrugBank: Mogamulizumab (DB12498)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mogamulizumab 1 mg/kg plus Nivolumab 240 mg
Trial: 34753871
Drug: Digital pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital pill system (DPS)
Trial: 34753870
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) interruption after achieving >99.5% host cell replacement in peripheral blood by day 147.
Trial: 34753894
Drug: mRNA-1273 COVID-19
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 COVID-19 vaccine (Moderna) - 2 doses
Trial: 34754193
Drug: Sevelamer Hydrochloride
RxNorm normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevelamer Hydrochloride (SH) 2,400 mg
Trial: 34754193
Drug: Lanthanum Carbonate
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lanthanum Carbonate (LC) 1,000 mg
Trial: 34754429
Drug: ADPKD-specific pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADPKD-specific pain assessment tool (APAT) administered longitudinally in a randomized high-water intake trial.
Trial: 34754429
Drug: Pain severity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain severity and associated analgesic use in ADPKD participants.
Trial: 34755131
Drug: Neoadjuvant nivolumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant nivolumab treatment
Trial: 34755137
Drug: Nivolumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (3 mg/kg) administered biweekly for 3 to 4 doses before surgery
Trial: 34756674
Drug: HDL particle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDL particle concentration < 3.5 μmol/L and total cholesterol ≤ 96 mg/dL in AH patients
Trial: 34757194
Drug: UV-oHSV2-stimulated NK92
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UV-oHSV2-stimulated NK92 cells with anti-NKG2A and anti-HLA-E treatment
Trial: 34757489
Drug: PIPAC-OX (oxaliplatin-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIPAC-OX (oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy)
Trial: 34757602
Drug: Pirfenidone tablets
RxNorm normalized name: Pirfenidone Tablets
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pirfenidone tablets
Trial: 34757602
Drug: Pirfenidone capsules
RxNorm normalized name: Pirfenidone Capsules
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pirfenidone capsules
Trial: 34757602
Drug: Pirfenidone (tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirfenidone (tablets and substitution)
Trial: 34757829
Drug: Advanced obesity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advanced obesity treatment
Trial: 34757973
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) adherence measured electronically in a subcohort of 324 clients.
Trial: 34758995
Drug: Dexmedetomidine (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (loading dose of 0.6 µg/kg in 10 min followed by continuous infusion at 0.4 µg/kg/hour until dural closure)
Trial: 34761160
Drug: 24-hour estimated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour estimated excretion from spot urine sample
Trial: 34762093
Drug: ATRA and
RxNorm normalized name: ATRA
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ATRA and arsenic trioxide regimen (chemotherapy-free) for standard-risk APL
Trial: 34762093
Drug: ATRA and
RxNorm normalized name: ATRA
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ATRA and arsenic trioxide regimen with 4 doses of idarubicin during induction therapy for high-risk APL
Trial: 34763665
Drug: D-chiro-inositol (DCI)
RxNorm normalized name: chiro-inositol, (+)-
DrugBank: D-chiro-Inositol (DB15350)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-chiro-inositol (DCI) 600 mg, two times per day for 30 days
Trial: 34763776
Drug: 0.10 or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.10 or 0.15 mL of MB
Trial: 34765307
Drug: Camrelizumab 200
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Camrelizumab 200 mg every 2 weeks until disease progression or unacceptable toxicity
Trial: 34765593
Drug: Kinect-Based Constraint-Induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinect-Based Constraint-Induced Therapy Program
Trial: 34766217
Drug: Polatuzumab vedotin-based
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Polatuzumab vedotin-based chemotherapy (including regimens other than BR)
Trial: 34766217
Drug: Polatuzumab vedotin-based
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Polatuzumab vedotin-based chemotherapy
Trial: 34766217
Drug: Polatuzumab vedotin-based
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Polatuzumab vedotin-based chemotherapy with subsequent hematopoietic stem cell transplantation (HSCT)
Trial: 34766576
Drug: Negative IgG
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative IgG anti-HAV antibody status
Trial: 34766576
Drug: Negative IgG
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative IgG HBV surface antibody status
Trial: 34766576
Drug: Association with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Association with use of anti-tumor necrosis factor agents
Trial: 34767652
Drug: Filgrastim at
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Filgrastim at 5 μg/kg in morbidly obese patients
Trial: 34767652
Drug: Filgrastim at
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Filgrastim at 5 μg/kg in non-obese patients
Trial: 34767652
Drug: Filgrastim dosing
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Filgrastim dosing based on actual body weight
Trial: 34767759
Drug: mRNA-1273 COVID-19
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 COVID-19 vaccine (100 μg in 0.5 mL intramuscularly, 2 doses, 28 days apart)
Trial: 34767765
Drug: Quadrivalent HPV
RxNorm normalized name: HPV, quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent HPV vaccine (HPV4) or nonavalent HPV vaccine (HPV9) administered in three doses over 6 months (on day 1, at month 2, and at month 6).
Trial: 34768176
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose protocol with prolonged infusion
Trial: 34768692
Drug: Biofeedback therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback therapy (BFT) performed once or twice a week during the temporary stoma period
Trial: 34772746
Drug: Meditation programme
RxNorm normalized name: benzalkonium chloride Topical Foam [Meditize]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meditation programme (12 weekly sessions of 1.5 hours each)
Trial: 34772758
Drug: Tremelimumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab (10 mg/kg) + MEDI3617 (200 mg)
Trial: 34772758
Drug: Tremelimumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab (10 mg/kg) + MEDI3617 (600 mg)
Trial: 34773596
Drug: fNIRS-guided rTMS
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fNIRS-guided rTMS treatment (n=20)
Trial: 34773596
Drug: MEP-guided rTMS
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEP-guided rTMS treatment (n=16)
Trial: 34775134
Drug: Intravenous colistin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous colistin methanesulfonate (CMS) at 2.5-5.0 mg/kg/day
Trial: 34775220
Drug: MK-1654 (neutralizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1654 (neutralizing monoclonal antibody)
Trial: 34775220
Drug: MK-1654 (≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1654 (≥ 75 mg)
Trial: 34778571
Drug: adjunctive dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: adjunctive dexamethasone
Trial: 34778701
Drug: New medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New medical therapy
Trial: 34778998
Drug: Sutimlimab, an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sutimlimab, an investigational C1s inhibitor
Trial: 34779146
Drug: short-term preoperative
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: short-term preoperative endocrine therapy (pET) with tamoxifen or aromatase inhibitors
Trial: 34779146
Drug: aromatase inhibitor-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aromatase inhibitor-based pET
Trial: 34780283
Drug: Loop Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loop Insulin Dosing System
Trial: 38101902
Drug: Milvexian 25
RxNorm normalized name: Milvexian
DrugBank: Milvexian (DB16233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milvexian 25 mg twice daily
Trial: 38101902
Drug: Milvexian 50
RxNorm normalized name: Milvexian
DrugBank: Milvexian (DB16233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milvexian 50 mg twice daily
Trial: 39214801
Drug: Milvexian 100
RxNorm normalized name: Milvexian
DrugBank: Milvexian (DB16233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milvexian 100 mg twice daily
Trial: 38101902
Drug: Milvexian 200
RxNorm normalized name: Milvexian
DrugBank: Milvexian (DB16233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milvexian 200 mg twice daily
Trial: 38101902
Drug: Milvexian 25
RxNorm normalized name: Milvexian
DrugBank: Milvexian (DB16233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milvexian 25 mg once daily
Trial: 34780683
Drug: Milvexian 50
RxNorm normalized name: Milvexian
DrugBank: Milvexian (DB16233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milvexian 50 mg once daily
Trial: 34780683
Drug: Milvexian 200
RxNorm normalized name: Milvexian
DrugBank: Milvexian (DB16233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milvexian 200 mg once daily
Trial: 34780709
Drug: Ceritinib 510
RxNorm normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ceritinib 510 mg/m²
Trial: 34780709
Drug: Ceritinib 500
RxNorm normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ceritinib 500 mg/m²
Trial: 34781168
Drug: LY2780301 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2780301 500 mg QD + paclitaxel 80 mg/m²
Trial: 34781168
Drug: LY2780301 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2780301 + weekly paclitaxel
Trial: 34781256
Drug: Sulfadoxine-pyrimethamine plus
RxNorm normalized name: pyrimethamine / sulfadoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine-pyrimethamine plus amodiaquine (5 monthly rounds)
Trial: 34784953
Drug: Pharmacotherapy for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy for AUD or referral for AUD services
Trial: 34785698
Drug: WT2725 dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WT2725 dosing emulsion